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Abstract:
Purpose: Report the clinical effect of femoropopliteal artery treatment 
with a drug-eluting stent in patients with long lesions. 
Methods: The global IMPERIAL Long Lesion sub-study is a prospective 
single-arm, multicenter trial of the Eluvia Drug-Eluting Vascular Stent 
System (Boston Scientific, Marlborough, MA, USA) for treating 
femoropopliteal artery lesions >140 mm and ≤190 mm in length. 
Primary patency (duplex ultrasound PSVR ≤2.4 in the absence of 
clinically-driven target lesion revascularization or bypass of the target 
lesion) and major adverse events (e.g., all causes of death through 1 
month, target limb major amputation through 12 months, or target 
lesion revascularization through 12 months) were assessed at 12 
months. 
Results: Fifty patients (mean age 68.2 years, 64% men) with mean 
lesion length 162.8 ± 34.7 mm were enrolled (40% with diabetes, 28% 
with severe calcification, 32% with occlusion). At 12 months, the Kaplan-
Meier estimate of primary patency was 87.9% and 93.5% of patients 
were free from major adverse events. No stent thrombosis was observed 
and no target limb amputations were performed. 
Conclusions: Results from the IMPERIAL Long Lesion sub-study 
demonstrate excellent patency and safety through 1 year among 
patients with long femoropopliteal occlusive disease treated with the 
Eluvia stent.
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JEVT-19-0350 Responses2Comments
Reviewer Comments to the Author:
Reviewer: 1
Thank you for submitting this paper, which demonstrates the efficacy of Eluvia stent in "long" lesions. 
Here are my comments:
1. [...]Stent diameters of 6 mm and 7 mm and lengths of 40-150 mm were available for use in the study. 
Use of overlapping stents was expected to cover the entire lesion length [...]: It is well known that a 
number of physicians faced problems with the initial 200mm device. Have you used these devices in this 
trial and if yes, have you excluded them?
Response: Eluvia was never available in 200mm lengths, but the reviewer may be referring to the 
150mm length which is not currently available commercially. The study was enrolled while the 
150mm length was commercially available in Europe, and patients treated with that length (36 of 94 
total stents implanted) are included in the analysis as noted in the Procedures section of the Results. 
No unanticipated adverse device events were reported in the study (with any length).
2. [...] dual antiplatelet therapy for the first 60 days post-procedure, and antiplatelet monotherapy 
through 12-month follow-up [...]: What did you recommend in patients on oral anticoagulation? 
Response: Patients on anticoagulation for comorbid conditions could be exempted from antiplatelet 
requirements if the addition of dual-antiplatelet therapy posed an intolerable bleeding risk in the 
opinion of the treating investigator. This protocol detail has been added to the revised text (page 5, 
last paragraph).
3. Why did you stop recruitment at 50 pts? I find this number a big limitation considering that you have 
recruited pts from 24 centres, i.e. 2 pts per centre.
Response: As stated in the Statistical Analysis section of the Methods, “The Long Lesion sub-study was 
exploratory, and the sample size was not determined statistically.” Sample size of 50 patients was 
specified in the study protocol prior to commencing enrollment. This number was not statistically-
driven, but was chosen to provide descriptive information regarding Eluvia performance in lesions 
longer than those allowed in the RCT portion of the IMPERIAL study. The enrollment distribution was 
uneven across centers.
4. Based on the current recommendations of ESC/ESVS guidelines 16 mm is not a long lesion anymore. It 
is, of course, longer than the lesions of the RCT but still not comparable to the studies regarding other 
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devices. I would rephrase the title because at the current form it is misleading: Eluvia is safe in long 
lesions (for the reader a long lesion is also 200 and 250 mm as well). 
Response: The title has been revised to specify the lesion length inclusion criteria; however, IMPERIAL 
“Long Lesion Substudy” is the name of the study as registered (clinicaltrials.gov NCT02574481) so we 
have not changed the subtitle portion that names the study. 
The sub-study objective statement has been revised to reduce emphasis on “long lesions” (page 4, 
first paragraph), and the Methods section now clarifies the desire to assess overlapping stent use 
(page 5, first paragraph). Although other types of study designs have previously included lengths >200 
mm, pivotal trials for FDA device approval have not. We also wanted to avoid including TASCII D 
lesions, which guidelines recommend treating with surgery.
The Discussion has been amended to emphasize the study objective of assessing overlapping device 
performance in a structured trial setting, which necessitated constraining the number of overlapping 
stents to be implanted and therefore the maximum lesion length; and to clarify limitations of 
generalizing the results to all “long” lesions (page 12, paragraph 2).
5. [...] The duplex ultrasound imaging finding observed in 4 patients was not associated with clinical 
sequelae, but the evolution of this phenomenon will be further assessed via transverse duplex 
ultrasound evaluations to be performed at future follow up visits. [...]: What kind of finding is that? I 
cannot find it in the Results section.
Response: Please see the response to comment 8.
6. [...] A retrospective single center review of Zilver PTX for long lesions reported 1-year restenosis >50% 
(based on duplex ultrasound peak systolic velocity ratio) for 19% of patients with lesions 20 cm or 
shorter (mean 13.9 cm) and 40% for patients with lesions longer than 20 cm (mean 33.0 cm) [...]: This is 
what I mean with my previous comment. You cannot compare the results of your study with the results 
of ZilverPTX study in lesions of 33cm. How should we call those lesions: ultralong? You have to be more 
precise in your title. 
Response: We agree that the <20 cm (mean 13.9 cm) subcohort from the Zilver PTX study is likely a 
better comparator than the >20 cm subcohort with mean length of 33 cm. Since neither group 
perfectly matches the IMPERIAL study cohort, and other unaccounted-for patient characteristics or 
study differences will also affect patient outcomes, we included both in the Discussion to provide a 
range of lesion lengths and corresponding restenosis rates for reference. We have revised the start of 
this paragraph to clarify that the referenced results are intended to provide a contextual range of 
expected efficacy, not direct comparisons with the IMPERIAL study results (page 11, paragraph 2).
7. [...] Results from the IMPERIAL Long Lesion sub-study demonstrate excellent treatment durability and 
safety through 1 year among patients with long femoropopliteal occlusive disease treated with the 
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Eluvia stent [...]: The right description would be instead of long to write ... among patients with 140-190 
mm fem pop disease. 
Response: The Conclusion has been revised as suggested.
8. In the study from Bisdas et al and in the IMPERIAL trial there were some concerns about positive 
remodeling / aneurysmatic degenaration of the aneurysm wall. Have you seen similar problems in your 
cohort?
Response: The ultrasound imaging finding described by Bisdas et al was observed in 4 patients 
enrolled in this cohort; these 4 were included in the number reported previously by Gray et al for the 
overall study. Clarifying information has been added to the Results (page 9, paragraph 3).
Reviewer: 2
In his study authors report the clinical effect of femoropopliteal artery treatment with a drug-eluting 
stent in patients with long lesions. This substudy is a prospective single-arm, multicenter trial of the 
Eluvia Drug-Eluting Vascular Stent System for treating femoropopliteal artery lesions >140 mm and ≤190 
mm in length.
9. I cannot understand why they limited the length to 190 mm, so the average around 160 mm is in the 
gray zone. I would call enrolled lesions as intermediate lesion instead than long lesions. i think this is the 
major limitation of the study. authors should explain this.
Response: Please see the response to Comment 4. In addition, the inclusion criterion of maximum 
length 190mm was based on visual assessment by the treating investigator; subsequent core lab 
analysis showed that lesion lengths actually ranged up to about 244 mm, with a median length of 180 
mm  (page 8, paragraph 1).
10. Population enrolled is 50 patients. How did they calculate the number? 
Response: Please see the response to comment 3.
11. I would suggest to present the primary patency and other endpoints at 12 months and within the 
follow-up window time ( 30 or 60 days).
Response: The follow up window was 12 months ± 30 days. The observed primary patency (87.0%) 
and TLR (6.5%) rates account for evaluations within this window. The Kaplan-Meier estimate of 
patency is shown through 13 months in Figure 2A. 
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12. In the discussion section they compared studies that treated long lesions. They should acknowledge 
this, so probably a shorter and more focused discussion could be better.
Response: We acknowledge the limited comparability between the reported study and previous 
studies due to differences in eligibility criteria and other factors. We have revised the Discussion to 
clarify that the referenced results are intended to provide a contextual range of expected efficacy, not 
direct comparisons with the IMPERIAL study results. The Discussion has also been amended to clarify 
limitations of generalizing the results to all “long” lesions (page 11, paragraph 2; page 12 paragraph 2).
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1
Effectiveness and safety of a paclitaxel-eluting stent for long superficial femoral artery lesions 
up to 190 mm: One-year outcomes of the single-arm IMPERIAL long lesion sub-study of the 
Eluvia drug-eluting stent
Abstract
Purpose
Report the clinical effect of femoropopliteal artery treatment with a drug-eluting stent in patients 
with long lesions. 
Methods 
The global IMPERIAL Long Lesion sub-study is a prospective single-arm, multicenter trial of 
the Eluvia Drug-Eluting Vascular Stent System (Boston Scientific, Marlborough, MA, USA) for 
treating femoropopliteal artery lesions >140 mm and ≤190 mm in length. Primary patency 
(duplex ultrasound PSVR ≤2.4 in the absence of clinically-driven target lesion revascularization 
or bypass of the target lesion) and major adverse events (e.g., all causes of death through 1 
month, target limb major amputation through 12 months, or target lesion revascularization 
through 12 months) were assessed at 12 months. 
Results 
Fifty patients (mean age 68.2 years, 64% men) with mean lesion length 162.8 ± 34.7 mm were 
enrolled (40% with diabetes, 28% with severe calcification, 32% with occlusion). At 12 months, 
the Kaplan-Meier estimate of primary patency was 87.9% and 93.5% of patients were free from 
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2
major adverse events. No stent thrombosis was observed and no target limb amputations were 
performed.
Conclusions
Results from the IMPERIAL Long Lesion sub-study demonstrate excellent patency and safety 
through 1 year among patients with long femoropopliteal occlusive disease treated with the 
Eluvia stent.
Clinical trial registration: ClinicalTrials.gov, identifier NCT02574481.
Key words: drug-eluting stent, paclitaxel, peripheral arterial disease
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Introduction
Endovascular treatment with angioplasty or bare-metal stenting of obstructive lesions in the 
superficial femoral artery (SFA) or proximal popliteal artery (PPA) is commonly practiced to 
alleviate symptoms of claudication or critical limb ischemia. However, restenosis of the treated 
lesion occurs at an unsatisfactory rate and may necessitate reintervention. Drug-coated and drug-
eluting therapies including stents and balloons have been developed with the aim of reducing 
reintervention rates by preventing restenosis. Complex (i.e., long, calcified, occluded) lesions 
commonly occur in the SFA/PPA segment and a significant number of patients who receive 
primary balloon angioplasty require a stent.1-4 Consequently, benefits of drug-eluting stents have 
been hypothesized for the femoropopliteal segment, particularly for complex lesions, but effects 
have not yet been clearly established.
Prospective clinical trial data on drug-eluting stent use in the SFA/PPA segment is gradually 
accumulating. The antirestenotic effect of a paclitaxel-coated stent compared with non-drug 
coated treatment was demonstrated in the Zilver PTX RCT5 and single arm studies.6 These were 
followed by the MAJESTIC first-in-human7 and the IMPERIAL randomized head-to-head 
studies of the paclitaxel-eluting Eluvia stent.8 Superior primary patency for Eluvia over Zilver 
PTX at one year was demonstrated in the randomized controlled trial, but in relatively short to 
moderate lesion lengths (mean lesion lengths of 81.8 mm and 86.5 mm for the Zilver PTX and 
Eluvia arms, respectively). Mean lesion length was even shorter in the Zilver PTX RCT9 
comparing Zilver PTX with bare metal stents (approximately 65 mm) and only approximately 
100 mm in the single arm study.6
To address the scarcity of available clinical trial data regarding drug-eluting stent effectiveness 
in patients with long lesions, a Long Lesion sub-study was conducted under the auspices of the 
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global IMPERIAL trial. The sub-study objective was to evaluate the safety and effectiveness of 
overlapping the Eluvia Drug-Eluting Vascular Stents System for treating long-length SFA 
lesions longer than those eligible for the randomized trial.
Methods
Study Design
The IMPERIAL trial includes 3 parts: the primary randomized trial, a pharmacokinetic sub-
study, and a prospective single-arm study of patients with long lesions. Primary results from the 
randomized study and the pharmacokinetic sub-study were published previously.8 Clinical sites 
participating in the randomized or pharmacokinetic IMPERIAL studies could also enroll patients 
in the single-arm, non-blinded Long Lesion sub-study. All patients in the non-randomized Long 
Lesion sub-study were treated with the Eluvia Vascular Stent System (Boston Scientific, 
Marlborough, MA, USA).
The Institutional Review Board, Independent Ethics Committee, or Research Ethics Board 
applicable to each study site provided ethical approval for the study protocol. Patients provided 
written informed consent to participate in the study. The lead author and study principal 
investigators had full access to the data in the study and take responsibility for its integrity and 
the data analysis. This trial is registered with ClinicalTrials.gov, identifier NCT02574481. 
The data and study protocol for this clinical trial may be made available to other researchers in 
accordance with the Boston Scientific Data Sharing Policy (http://www.bostonscientific.com/en-
US/data-sharing-requests.html).
Participants
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Patient eligibility criteria for the IMPERIAL Long Lesion sub-study were identical to those 
applied in the randomized study8 with the exception of lesion length. Briefly, adults at least 18 
years of age with symptomatic lower limb ischemia (Rutherford category 2, 3, or 4) and stenotic 
or occlusive lesions in the native SFA or PPA, stenosis of ≥70% (visual angiographic 
assessment), and vessel diameter ≥4mm and ≤6mm were eligible. Total lesion length >140 mm 
and ≤190 mm (visual angiographic assessment) was required for inclusion in the Long Lesion 
sub-study; patients with lesions ≤140 mm could be enrolled in the randomized study. The 
eligible range of 140 to 190 mm was determined by the objective of assessing performance of 
two overlapping Eluvia stents to cover the entire stent length in accordance with the device 
Directions for Use (i.e., with 5 mm stent overlap and 5 mm extension into healthy tissue). 
Targeting lesions ≤190 mm (ie, TASCII D) also aligned with contemporary recommendations 
for endovascular rather than surgical treatment.10 
Procedures
The self-expanding nitinol Eluvia Stent is coated with a biostable polymer (poly vinylidene 
fluoride-co-hexafluoropropylene) and paclitaxel at a dose density of 0.167 µg paclitaxel per mm2 
stent surface area. Stent diameters of 6 mm and 7 mm and lengths of 40-150 mm were available 
for use in the study. Use of two overlapping stents was expected to cover the entire lesion length.
At a minimum, anticoagulation and antiplatelet therapy required clopidogrel or ticlopidine 
starting at least 24 hours prior to the procedure or a peri-procedural loading dose, dual 
antiplatelet therapy for the first 60 days post-procedure, and antiplatelet monotherapy through 
12-month follow-up. Antiplatelet monotherapy was recommended through trial completion at 5 
years. Patients on anticoagulation for comorbid conditions could be exempted from antiplatelet 
Commented [DE3]:  Comment 4
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requirements if, in the opinion of the treating investigator, the addition of dual-antiplatelet 
therapy posed an intolerable bleeding risk.
Endpoints and Follow-up
The primary effectiveness endpoint was 12-month (± 30 days) primary patency. Primary vessel 
patency was defined as duplex ultrasound peak systolic velocity ratio ≤ 2.4 as assessed by a core 
laboratory (VasCore, Boston, MA, USA), in the absence of clinically-driven target lesion 
revascularization (TLR) or bypass of the target lesion. Clinically-driven TLR was defined as a 
reintervention within 5 mm proximal or distal to the original treatment segment for ≥50% 
angiographic diameter stenosis in the presence of recurrent symptoms (≥ 1 change in Rutherford 
class) or associated with decreased ankle-brachial index of ≥20% or ≥ 0.15 in the treated 
segment. 
The primary safety endpoint was 12-month freedom from major adverse events (MAEs), defined 
as all causes of death through 1 month, target limb major amputation through 12 months, or TLR 
through 12 months. A Clinical Events Committee adjudicated all deaths, amputations, TLRs, and 
stent thrombosis.
Procedural success was defined as technical success (ie, delivery and deployment of the assigned 
study stent to the target lesion with residual angiographic stenosis no greater than 30% as 
assessed by the implanting investigator) with no MAEs within 24 hours of the index procedure.
Twelve-month follow-up included stent integrity, clinical outcome, and health-related quality of 
life assessments. Radiographs obtained at the 12-month visit were evaluated by an independent 
core laboratory (VasCore, Boston, MA, USA). Possible fractures were verified by comparison 
with procedural angiography by the angiographic core laboratory (Beth Israel Deaconess 
Commented [DE5]:  Comment 2
Commented [DE6]:  Comment 11
Page 10 of 30
https://mc.manuscriptcentral.com/jevt
Journal of Endovascular Therapy
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
7
Medical Center, Boston, MA, USA). Clinical improvement was assessed with Rutherford 
categorization and walking function was evaluated with the Walking Impairment Questionnaire 
(WIQ) and 6-minute walk test. Hemodynamic improvement was defined as an ankle-brachial 
index (ABI) increase by ≥ 0.1 as compared with the pre-procedure value or to an ABI ≥ 0.90, 
without TLR. General health status was assessed with the EQ-5D questionnaire. Hospitalizations 
associated with TLR, target vessel revascularization, or procedure- or device-related adverse 
events were counted through 1 year post-procedure.
Statistical Analysis 
The Long Lesion sub-study was exploratory, and the sample size was not determined 
statistically. For the primary effectiveness endpoint assessment, the observed primary patency 
rate was compared with a non-statistically based performance goal of 60%. The performance 
goal was determined by adding 10% (estimated drug effect) to the historical patency rate for long 
lengths of the bare nitinol stent platform.11
No hypothesis testing was performed for the primary safety endpoint, but the MAE-free rate was 
expected to be similar to that reported at 12 months for the IMPERIAL randomized study (i.e., 
95%).8 
Categorical variables are reported as counts and percentages and continuous variables are 
reported as mean (SD). The Kaplan-Meier product-limit method was used to estimate the time-
to-event-free rates for primary patency and freedom from TLR. Paired t-tests were used to 
compare follow-up outcome scores with baseline values; a p value of less than 0.05 indicated 
statistical significance. Analyses were performed with Statistical Analysis Software (SAS), 
version 9.2 or later (SAS Institute Inc., Cary, North Carolina).
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Results
Patients
A total of 50 patients at 24 IMPERIAL clinical sites in Austria, Belgium, Japan, New Zealand, 
and the USA were enrolled in the Long Lesion sub-study. Patient baseline characteristics are 
summarized in Table 1. Forty percent of patients had diabetes and 32% were current smokers. As 
determined by the angiographic core laboratory, mean lesion length was 162.8±34.7 mm 
(median 180 mm, interquartile range 160-190 mm), 70% had moderately or severely calcified 
lesions, and 32% had occlusions. No deaths occurred during 12 months of follow-up and one 
patient withdrew from the study (Figure 1).
Procedures
A total of 94 stents were implanted in the 50 patients (mean of 1.9 stents per patient). Sixty two 
percent (58/94) of stents were lengths of 40-120 mm and the remainder were 150 mm in length. 
Balloon predilatation was performed in 88% (44/50) of patients. The procedure success rate was 
98% (49/50); residual stenosis >30% was reported by the investigative site for one patient and no 
MAEs were reported within 24 hours of the procedures.
Dual antiplatelet therapy was reported for 84% (42/50) of patients at both discharge and 1 month 
post-procedure. Acetylsalicylic acid use was reported by 89% (40/45) of patients at 12 months, 
with dual antiplatelet therapy continuing for 73.3% (33/45). 
Effectiveness and Safety
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The observed primary patency rate was 87.0% at 12 months (Table 2), which exceeded the 
performance goal. The Kaplan-Meier estimate of primary patency was 87.9% at 12 months 
(Figure 2). 
The MAE-free rate at 12 months was 93.5% (Table 2) due to 3 TLR procedures. All TLRs were 
considered clinically-driven. No deaths occurred through 12 months. No stent thrombosis was 
observed and no target limb amputations were performed. 
Among patients in the Long Lesion sub-study with suitable ultrasound imaging (transverse 
ultrasound imaging was not systematically performed for all patients), the ultrasound core 
laboratory identified 4 patients with a suspected localized inflammatory response characterized 
by a hypoechoic halo around the stent. These 4 cases from the Long Lesion cohort were included 
in the number reported previously for the overall study.12 All 4 patients’ stents were patent and 
none had a stent thrombosis or TLR through one year.
One patient with two stents had radiographically and angiographically-confirmed fracture in both 
stents, both were grade V mid-stent fractures.13 Both stents were patent at 12-month follow up 
with no associated complications or adverse events. 
Clinical Outcomes and Hospitalization
A total of 91.5% (43/47) of patients had Rutherford category improvement without the need for 
TLR and 87.2% (41/47) were classified as Rutherford category 0 or 1 at 12 months (Figure 3). 
Hemodynamic improvement (i.e., ABI improvement without reintervention) was observed in 
82.2% (37/45) of patients.
Walking function improved from baseline, with the overall WIQ score improving from 
49.48±28.94 at baseline to 80.32±24.97 (p<0.0001) at 12 months in addition to significantly 
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improved distance, speed, and stair climbing scores (Table 3). Walking distance and speed also 
increased based on the 6-minute walk test, with mean distance walked increasing from 
240.0±147.8 m to 293.5±123.8 m and speed increasing from 44.2 ±21.9 m/min to 50.3 ±19.3 
m/min (p=0.009). 
Although average EQ-5D health-related quality of life index scores remained consistent over the 
course of the study, the proportions of patients reporting “no problems” related to mobility, usual 
activities, and pain increased after treatment (Table 4).
No patients required inpatient hospitalization due to TLR, TVR, or procedure- or device-related 
adverse events during 12-month follow-up.
Discussion
A 12-month primary patency rate of 88.5% (Kaplan-Meier estimate) and MAE rate of 4.9% was 
previously shown for patients who were treated with Eluvia in the IMPERIAL RCT (mean lesion 
length 86.5 mm).8 Results of the IMPERIAL Long Lesion sub-study, which enrolled a separate 
set of patients with mean lesion length approximately double that of the RCT (162.8 mm), were 
remarkably similar at 1 year, with a primary patency rate of 87.9% and MAE rate of 6.5%. 
Although the Long Lesion sub-study had a relatively small sample size, the results suggest that 
1-year patency with the Eluvia drug-eluting stent was independent of lesion length. These 
consistent results were observed despite the presence of additional factors generally associated 
with poorer patency outcomes, such as calcified lesions (moderate or severe in 70% of patients) 
and occlusions (present in 32% of patients), which are also more representative of real-world 
clinical populations. No significant safety events occurred. The duplex ultrasound imaging 
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finding observed in 4 patients was not associated with clinical sequelae, but the evolution of this 
phenomenon will be further assessed via transverse duplex ultrasound evaluations to be 
performed at future follow up visits.
These results compare favorably withComparisons with previous previous studies of paclitaxel-
eluting stent use in long lesions. are limited due to differences across clinical studies, including 
lesion length inclusion criteria and other baseline characteristics. However, these studies provide 
a range of reference and context for the IMPERIAL study results. In a registry of Eluvia use at a 
single European center, a 12-month primary patency rate of 87% in patients with a mean lesion 
length of 20 cm (48% with critical limb ischemia) was reported,14 further supporting the notion 
of independence between patency and lesion length for patients treated with Eluvia. Treatment of 
long lesions with the paclitaxel-coated Zilver PTX stent yielded 1-year primary patency rates of 
52.5% in a single-center registry in France (mean lesion length 25 cm, 51% with critical limb 
ischemia at baseline)15 and 86.4% in a multicenter registry in Japan (mean lesion length 14.7 cm, 
21.5% with critical limb ischemia).16 A retrospective single center review of Zilver PTX for long 
lesions17 reported 1-year restenosis >50% (based on duplex ultrasound peak systolic velocity 
ratio) for 19% of patients with lesions 20 cm or shorter (mean 13.9 cm) and 40% for patients 
with lesions longer than 20 cm (mean 33.0 cm). More long-term follow-up data are needed to 
evaluate the benefits of drug-eluting stents for long lesions, particularly in comparison with drug-
coated balloon treatment.
Drug-coated balloon treatment is easily customized to lesion length, but stand-alone use in long 
femoropopliteal lesions has not demonstrated durability over time. Treatment with the In.Pact 
paclitaxel-coated balloon resulted in 1-year patency rates of 76-83% (reported primary patency 
or binary restenosis) across three studies with mean lesion lengths ranging from 19-25 cm.2-4 At 
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2 years, the reported patency rates declined to 54% and 70%.2,3 Treatment with the Lutonix 
paclitaxel-coated balloon likewise showed a steep decline in patency among patients with long 
lesions (mean length 21 cm) in the Lutonix Global SFA Registry; by 2 years the patency rate was 
67%.1 Drug-coated balloon treatment was compared with Zilver PTX drug-coated stent treatment 
in the randomized 150-patient REAL-PTX pilot study.18 Study results suggested a non-
significant advantage for the stent only after 2 and 3 years, with the differential effect most 
pronounced among patients with lesions longer than 10 cm.18 These preliminary observations are 
limited by the very small sample size with long lesions and long term follow-up in the pilot 
study. Whether drug-eluting stent treatment proves to overcome the limitations of drug-coated 
balloon treatment in long femoropopliteal segment lesions over time remains to be seen.
Limitations of the IMPERIAL Long Lesion sub-study include the short duration of follow-up to 
date. Follow-up is ongoing and duplex ultrasound patency assessments will be repeated at 2 
years and at the final 5-year follow-up visit. The lesion length inclusion criteria were “long” 
relative to the randomized portion of the IMPERIAL trial, which included lengths less than 140 
mm, but were constrained to a maximum of 190 mm in order to assess performance of two 
overlapping stents in a structured trial setting. The range of 140 to 190 mm as defined by the 
inclusion criteria yielded a mean length of 162.8 mm by core lab assessment, which may not be 
considered “long” according to current guidelines,19 and the study results may not be 
generalizable to lesions longer than those studied here. The study does not directly address 
possible advantages of long, single stent placement compared with stent overlap when two or 
more stents are implanted. The single-arm, non-comparative design as well as the relatively 
small number of treated patients also limit the generalizability of the study results. 
Conclusion
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Results from the IMPERIAL Long Lesion sub-study demonstrate excellent treatment durability 
and safety through 1 year among patients with long femoropopliteal occlusive disease up to 190 
cm long treated with the Eluvia stent.   
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Figure Legends
Figure 1. Patient flow
Figure 2. Kaplan-Meier estimate of primary patency (A) and target lesion revascularization (B), 
with standard errors. 
Figure 3. Rutherford category distribution
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Table 1. Baseline patient and lesion characteristics
Characteristic N=50
Age (years) 68.2±8.9
Male sex 64.0% (32)
Race or ethnicity
Hispanic or Latino 6.0% (3)
Caucasian 60.0% (30)
Asian 22.0% (11)
Black, or African heritage 12.0% (6)
Smoking status
Current 32.0% (16)
Previous 52.0% (26)
Diabetes mellitus 40.0% (20)
Type 1 5.0% (1)
Type 2 90.0% (18)
Unknown 5.0% (1)
Hyperlipidemia 82.0% (41)
Hypertension 92.0% (46)
Coronary artery disease 56.0% (28)
Myocardial infarction 18.0% (9)
Congestive heart failure 16.0% (8)
Renal insufficiency 6.0% (3)
Angiographic Characteristicsa
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Arterial Segmentsb
Ostial 2.0% (1)
Proximal 54.0% (27)
Mid 90.0% (45)
Distal (including proximal popliteal) 76.0% (38)
Length (mm)c 162.8±34.7
Reference vessel diameter (mm) 4.7±0.7
Calcificationd
None/Mild 28.0% (14)
Moderate 42.0% (21)
Severe 28.0% (14)
Unknown 2.0% (1)
% Diameter Stenosis 81.9%±15.0%
<50% 2.0% (1)
50%-99% 66.0% (33)
100% (Occlusion) 32.0% (16)
Ankle brachial index 0.7±0.2
Mean ± SD or % (n). 
aAngiographic characteristics are based on core laboratory assessment.
bMore than one arterial segment per patient was allowed.
cInclusion criterion was based on operator assessment of lesion length; lesion length was 
subsequently assessed by the core laboratory.
Page 25 of 30
https://mc.manuscriptcentral.com/jevt
Journal of Endovascular Therapy
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
dCalcification was assessed by the core laboratory. Moderate calcification defined as 
radiopacities noted on one side of the arterial wall or less than one cm of length prior to contrast 
injection or digital subtraction. Severe calcification defined as radiopacities noted on both sides 
of the arterial wall and extending more than 1 cm of length prior to contrast injection or digital 
subtraction.
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Table 2. Efficacy and safety results 
Event Rate
Primary patencya 87.0% (40/46)
MAE-free 93.5% (43/46)
MAE 6.5% (3/46)
All-cause death at 1 month 0.0% (0/46)
Target limb major amputation 0.0% (0/46)
Target lesion revascularization 6.5% (3/46)
Stent thrombosis 0.0% (0/46)
All-cause death through 12 months 0.0% (0/46)
MAE, major adverse event. 
aPercentage of target stented segments with duplex ultrasound peak systolic velocity ratio ≤ 2.4, 
in the absence of clinically-driven target lesion revascularization or bypass of the target lesion.
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Table 3. Walking Impairment Questionnaire (WIQ) results
Baseline 1 Month 6 Months 12 Months
N 48 50 48 47
Distance 32.16±30.05 57.90±34.54 64.21±35.27 58.67±36.60
Change from Baseline 26.95±32.66 31.80±41.90 26.45±35.34
p <0.001 <0.001 <0.001
Speed 28.44±23.06 40.15±22.85 43.66±27.14 41.21±25.95
Change from Baseline 12.93±28.17 15.31±33.28 11.50±30.94
p 0.003 0.003 0.017
Stair Climbing 35.85±30.68 60.00±32.59 56.77±33.25 56.29±34.55
Change from Baseline 25.17±31.09 20.20±43.32 18.33±38.44
p <0.001 0.003 0.003
Walking Impairment 49.48±28.94 83.00±24.45 86.46±17.83 80.32±24.97
Change from Baseline 32.81±35.04 36.41±34.84 31.11±35.42
p <0.001 <0.001 <0.001
Values reported as mean ± SD. P values from paired t-test.
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Table 4. EQ-5D Health Status
Baseline 1 Month 6 Months 12 Months
N 48 50 48 47
EQ-5D Dimensiona
Mobility
No problems 10.4% (5) 46.0% (23) 39.6% (19) 44.7% (21)
Slight problems 25.0% (12) 32.0% (16) 37.5% (18) 21.3% (10)
Moderate problems 43.8% (21) 16.0% (8) 18.8% (9) 21.3% (10)
Severe problems 20.8% (10) 6.0% (3) 4.2% (2) 12.8% (6)
Unable 0.0% (0) 0.0% (0) 0.0% (0) 0.0% (0)
Personal Care
No problems 93.8% (45) 96.0% (48) 93.8% (45) 87.2% (41)
Slight problems 6.3% (3) 2.0% (1) 4.2% (2) 4.3% (2)
Moderate problems 0.0% (0) 0.0% (0) 0.0% (0) 6.4% (3)
Severe problems 0.0% (0) 2.0% (1) 2.1% (1) 2.1% (1)
Unable 0.0% (0) 0.0% (0) 0.0% (0) 0.0% (0)
Usual Activities
No problems 45.8% (22) 60.0% (30) 72.9% (35) 72.3% (34)
Slight problems 29.2% (14) 30.0% (15) 12.5% (6) 12.8% (6)
Moderate problems 16.7% (8) 10.0% (5) 10.4% (5) 12.8% (6)
Severe problems 6.3% (3) 0.0% (0) 4.2% (2) 2.1% (1)
Unable 2.1% (1) 0.0% (0) 0.0% (0) 0.0% (0)
Pain/ Discomfort
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None 16.7% (8) 42.0% (21) 50.0% (24) 46.8% (22)
Slight 33.3% (16) 36.0% (18) 37.5% (18) 31.9% (15)
Moderate 29.2% (14) 12.0% (6) 10.4% (5) 14.9% (7)
Severe 20.8% (10) 10.0% (5) 2.1% (1) 4.3% (2)
Extreme 0.0% (0) 0.0% (0) 0.0% (0) 2.1% (1)
Anxiety/ Depression
None 66.7% (32) 74.0% (37) 70.8% (34) 72.3% (34)
Slight 22.9% (11) 16.0% (8) 25.0% (12) 21.3% (10)
Moderate 8.3% (4) 6.0% (3) 4.2% (2) 6.4% (3)
Severe 2.1% (1) 4.0% (2) 0.0% (0) 0.0% (0)
Extreme 0.0% (0) 0.0% (0) 0.0% (0) 0.0% (0)
Summary Indexb 0.8±0.1 0.8±0.1 0.8±0.1 0.8±0.1
Visual Analogue Scalec 67.5±18.5 75.4±16.4 74.4±17.2 70.6±20.6
aValues reported as % (n) of patients reporting problems with each dimension.
bSummary index values calculated based on the United States value set; reported as mean ± SD.
cVisual Analogue Scale (VAS) ranged from 0 (worst imaginable health state) to 100 (best 
imaginable health state); reported as mean ± SD.
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